



EXPRESS MAIL NO. EV889156122US

PATENT

THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Christen M. Anderson et al.  
Application No. : 10/763,398  
Filed : January 23, 2004  
For : PRODUCTION OF ADENINE NUCLEOTIDE TRANSLOCATOR  
(ANT), NOVEL ANT LIGANDS AND SCREENING ASSAYS  
THEREFOR

Examiner : Billy D. Chism  
Art Unit : 1654  
Docket No. : 660088.443C1  
Date : February 8, 2007

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

AMENDMENT AND RESPONSE TO OFFICE COMMUNICATION

Commissioner for Patents:

In response to the Office Communication dated January 17, 2007, (hereinafter, "PTO"), Applicants hereby wish to clarify that the recitation "SEQ ID NO:33" has previously been amended in the specification to "SEQ ID NO:6", and that the recitation "SEQ ID NO:33" in the claims is presently amended to "SEQ ID NO:6". Due to an inadvertent typographical error in the Response to Restriction Requirement submitted to the PTO on October 20, 2006, "SEQ ID NO:33" was specified as a further election of species, when in fact the clear intent from the record as a whole is that "SEQ ID NO:6" was being designated.

Specifically, in the Response submitted to the PTO on October 20, 2006, election was made of Group I, claims 113-116, with the further election, as the single disclosed species, of an isoform-specific antibody that recognizes a human adenine nucleotide translocator 3

polypeptide having an amino acid sequence as set forth in "SEQ ID NO:33." For reasons given herein, the election was clearly intended to be of Group I, claims 113-116, with the further election, as the single disclosed species, of an isoform-specific antibody that recognizes a human adenine nucleotide translocator 3 polypeptide having an amino acid sequence as set forth in SEQ ID NO:6. Accordingly, in view of the present correction of the species election which, as discussed further in the accompanying Remarks, is merely correction of a typographical error that is consistent with the record for the application, there is no deficiency in the compliance of the application with the sequence rules, 37 C.F.R. 1.821 – 1.825. Reconsideration of the application is therefore respectfully requested.

Please amend the application as follows:

**Amendments to the Claims** are reflected in the listing of claims which begins on page 3 of this paper.

**Remarks** begin on page 8 of this paper.